Cangrelor (BioDeep_00000169778)

   

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


[dichloro({[({[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-{[2-(methylsulfanyl)ethyl]amino}-2-[(3,3,3-trifluoropropyl)sulfanyl]-9H-purin-9-yl)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl})methyl]phosphonic acid

化学式: C17H25Cl2F3N5O12P3S2 (774.9483)
中文名称: 坎格雷洛
谱图信息: 最多检出来源 Homo sapiens(blood) 100%

分子结构信息

SMILES: CSCCNC1=C2C(=NC(=N1)SCCC(F)(F)F)N(C=N2)C3C(C(C(O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O
InChI: InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1

描述信息

Cangrelor (trade name: Kengreal (US), Kengrexal (Europe)) is a P2Y12 antagonist FDA approved as an antiplatelet drug that is administered intravenously to reduce ischemic events (i.e. restricted blood flow) in patients undergoing percutaneous coronary intervention (PCI). PCI, also known as coronary angioplasty, is a nonsurgical procedure which opens blocked or narrowed coronary arteries that are clogged due to a buildup of plaque. Being an adenosine triphosphate (ATP) analogue, cangrelor is able to bind the adenosine diphosphate (ADP) receptor P2Y12 and inhibit ADP-mediated platelet activation and aggregation. An advantage cangrelor provides over oral P2Y12 inhibitors (e.g. clopidogrel, ticagrelor, ticlopidine, and prasugrel) is that it is an active drug not requiring hepatic conversion, therefore, providing a rapid onset and offset of action (PMID: 27729681).
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent > C190801 - P2Y12 Inhibitor
D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists
D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors

同义名列表

8 个代谢物同义名

[dichloro({[({[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-{[2-(methylsulfanyl)ethyl]amino}-2-[(3,3,3-trifluoropropyl)sulfanyl]-9H-purin-9-yl)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl})methyl]phosphonic acid; N(6)-(2-Methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5-adenylic acid monoanhydride with dichloromethylenebis(phosphonic acid); Cangrelor tetrasodium; AR C69931MX; AR-C69931MX; Cangrelor; Kengrexal; Kengreal



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Natalia Rukoyatkina, Valentina Shpakova, Alina Bogoutdinova, Alexandra Kharazova, Igor Mindukshev, Stepan Gambaryan. Curcumin by activation of adenosine A2A receptor stimulates protein kinase a and potentiates inhibitory effect of cangrelor on platelets. Biochemical and biophysical research communications. 2022 01; 586(?):20-26. doi: 10.1016/j.bbrc.2021.11.006. [PMID: 34823218]
  • Xiao Zuo, Qing Li, Fuli Ya, Li-Juan Ma, Zezhong Tian, Mingzhu Zhao, Die Fan, Yimin Zhao, Yu-Heng Mao, Jian-Bo Wan, Yan Yang. Ginsenosides Rb2 and Rd2 isolated from Panax notoginseng flowers attenuate platelet function through P2Y12-mediated cAMP/PKA and PI3K/Akt/Erk1/2 signaling. Food & function. 2021 Jul; 12(13):5793-5805. doi: 10.1039/d1fo00531f. [PMID: 34041517]
  • Asami Kamada, Mie Shimizu, Kazumasa Oura, Makiko Yoshida, Keisuke Tsuda, Kiyotaka Oi, Yoko Ishigaku, Tatsunori Natori, Shinsuke Narumi, Ryo Itabashi, Tetsuya Maeda, Yasuo Terayama. Inhibitory Effects of P2Y12 Receptor Antagonist on PAR1- and PAR4-AP-Induced Platelet Aggregation in Patients with Stroke or TIA. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2021 Mar; 30(3):105547. doi: 10.1016/j.jstrokecerebrovasdis.2020.105547. [PMID: 33360254]
  • Italo Linfante, Kaushik Ravipati, Amy Kathryn Starosciak, Dennys Reyes, Guilherme Dabus. Intravenous cangrelor and oral ticagrelor as an alternative to clopidogrel in acute intervention. Journal of neurointerventional surgery. 2021 Jan; 13(1):30-32. doi: 10.1136/neurintsurg-2020-015841. [PMID: 32414891]
  • Osman Mutluhan Ugurel, Ozal Mutlu, Emrah Sariyer, Sinem Kocer, Erennur Ugurel, Tugba Gul Inci, Oguz Ata, Dilek Turgut-Balik. Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13). International journal of biological macromolecules. 2020 Nov; 163(?):1687-1696. doi: 10.1016/j.ijbiomac.2020.09.138. [PMID: 32980406]
  • Emmanuelle Scala, Christiane Gerschheimer, Francisco J Gomez, Lorenzo Alberio, Carlo Marcucci. Potential and Limitations of the New P2Y12 Inhibitor, Cangrelor, in Preventing Heparin-Induced Platelet Aggregation During Cardiac Surgery: An In Vitro Study. Anesthesia and analgesia. 2020 08; 131(2):622-630. doi: 10.1213/ane.0000000000004700. [PMID: 32102014]
  • Gordon G Paterson, Jason M Young, Joseph A Willson, Christopher J Graham, Rebecca C Dru, Eleanor W Lee, Greig S Torpey, Sarah R Walmsley, Melissa V Chan, Timothy D Warner, John Kenneth Baillie, Alfred Arthur Roger Thompson. Hypoxia Modulates Platelet Purinergic Signalling Pathways. Thrombosis and haemostasis. 2020 Feb; 120(2):253-261. doi: 10.1055/s-0039-3400305. [PMID: 31858521]
  • Tasuku Sakayori, Keisuke Kitano, Yuri Watanabe, Yukari Omori, Hidekazu Ishida, Nobuo Arai, Kodai Uematsu, Yukiko Enomoto, Yutaka Komiyama. Evaluation of the Newly Developed Adenosine Diphosphate-Induced Platelet Aggregation Level System in Aggregometer on Automated Coagulation Analyzer. Clinical laboratory. 2019 Dec; 65(12):. doi: 10.7754/clin.lab.2019.190353. [PMID: 31850712]
  • Alexander M Girgis, Dalia A Banks. In Response. A&A practice. 2019 11; 13(9):367. doi: 10.1213/xaa.0000000000001095. [PMID: 31609718]
  • Kenichi A Tanaka, Reney Henderson, Brittney Williams. Heparin-Induced Thrombocytopenia and Cardiac Surgery: Can We Do It All With Cangrelor?. A&A practice. 2019 11; 13(9):366. doi: 10.1213/xaa.0000000000001094. [PMID: 31567127]
  • Alexander M Girgis, Eugene Golts, Doug Humber, Dalia A Banks. Successful Use of Cangrelor and Heparin for Cardiopulmonary Bypass in a Patient With Heparin-Induced Thrombocytopenia and End-Stage Renal Disease: A Case Report. A&A practice. 2019 Jul; 13(1):10-12. doi: 10.1213/xaa.0000000000000969. [PMID: 30688681]
  • Rajiv A Kabadi, Ilya M Danelich, John W Entwistle, Gregary D Marhefka, Gordon Reeves, Andrew J Boyle, Ataul M Qureshi. Use of Cangrelor as a Bridge to Left Ventricular Assist Device Implantation in a Patient with a Recent Drug-Eluting Stent Who Developed Acute Tirofiban-Related Thrombocytopenia. Pharmacotherapy. 2019 04; 39(4):521-525. doi: 10.1002/phar.2219. [PMID: 30644585]
  • Magdalena Boncler, Joanna Wzorek, Nina Wolska, Dawid Polak, Cezary Watala, Marcin Rozalski. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y12 antagonists. Vascular pharmacology. 2019 02; 113(?):47-56. doi: 10.1016/j.vph.2018.11.005. [PMID: 30471364]
  • Maryna Masyuk, Nadia Heramvand, Johanna M Muessig, Amir M Nia, Amin Polzin, Markus Kollmann, Malte Kelm, Christian Jung. Pharmacosimulation of interruptions and its solution in intravenous administration of cangrelor. Clinical hemorheology and microcirculation. 2018; 68(4):421-425. doi: 10.3233/ch-170323. [PMID: 29036802]
  • Michal Droppa, Tobias Geisler. What is the Role of Cangrelor in Patients Undergoing PCI?. Current vascular pharmacology. 2018; 16(5):484-489. doi: 10.2174/1570161116666180117105834. [PMID: 29345586]
  • A J Gerrits, J A Jakubowski, A Sugidachi, A D Michelson, A L Frelinger. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor. Journal of thrombosis and haemostasis : JTH. 2017 05; 15(5):858-867. doi: 10.1111/jth.13627. [PMID: 28092426]
  • Piotr Adamski, Urszula Adamska, Małgorzata Ostrowska, Marek Koziński, Jacek Kubica. New directions for pharmacotherapy in the treatment of acute coronary syndrome. Expert opinion on pharmacotherapy. 2016 Dec; 17(17):2291-2306. doi: 10.1080/14656566.2016.1241234. [PMID: 27677394]
  • NULL. intravenous cangrelor (Kengrexal°) and coronary angioplasty: No advantage over first-line clopidogrel. Prescrire international. 2016 Oct; 25(175):235-236. doi: NULL. [PMID: 30645826]
  • Bincy Jose, Peter McCluskey, Niamh Gilmartin, Martin Somers, Dermot Kenny, Antonio J Ricco, Nigel J Kent, Lourdes Basabe-Desmonts. Self-Powered Microfluidic Device for Rapid Assay of Antiplatelet Drugs. Langmuir : the ACS journal of surfaces and colloids. 2016 Mar; 32(11):2820-8. doi: 10.1021/acs.langmuir.5b03540. [PMID: 26910300]
  • Thomas Gremmel, Ivan B Yanachkov, Milka I Yanachkova, George E Wright, Joseph Wider, Vishnu V R Undyala, Alan D Michelson, Andrew L Frelinger, Karin Przyklenk. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arteriosclerosis, thrombosis, and vascular biology. 2016 Mar; 36(3):501-9. doi: 10.1161/atvbaha.115.306885. [PMID: 26743169]
  • Ivan B Yanachkov, Hung Chang, Milka I Yanachkova, Edward J Dix, Michelle A Berny-Lang, Thomas Gremmel, Alan D Michelson, George E Wright, Andrew L Frelinger. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. European journal of medicinal chemistry. 2016 Jan; 107(?):204-18. doi: 10.1016/j.ejmech.2015.10.055. [PMID: 26588064]
  • Cynthia L Green, David J Whellan, Lindsay Lambe, S E Bellibas, Peter Wijngaard, Jayne Prats, Mitchell W Krucoff. Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study. Journal of cardiovascular pharmacology. 2013 Nov; 62(5):466-78. doi: 10.1097/fjc.0b013e3182a2630d. [PMID: 23921301]
  • Nizar Serhan, Cendrine Cabou, Céline Verdier, Laeticia Lichtenstein, Nicole Malet, Bertrand Perret, Muriel Laffargue, Laurent O Martinez. Chronic pharmacological activation of P2Y13 receptor in mice decreases HDL-cholesterol level by increasing hepatic HDL uptake and bile acid secretion. Biochimica et biophysica acta. 2013 Apr; 1831(4):719-25. doi: 10.1016/j.bbalip.2012.12.006. [PMID: 23266391]
  • Timothy J Stalker, Elizabeth A Traxler, Jie Wu, Kenneth M Wannemacher, Samantha L Cermignano, Roman Voronov, Scott L Diamond, Lawrence F Brass. Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. Blood. 2013 Mar; 121(10):1875-85. doi: 10.1182/blood-2012-09-457739. [PMID: 23303817]
  • Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals. 2012 Dec; 40(12):2332-41. doi: 10.1124/dmd.112.047068. [PMID: 22961681]
  • Sukit M Ringwala, Peter M Dibattiste, David J Schneider. Effects on platelet function of a direct acting antagonist of coagulation factor Xa. Journal of thrombosis and thrombolysis. 2012 Oct; 34(3):291-6. doi: 10.1007/s11239-012-0727-5. [PMID: 22528328]
  • Yue Liu, Hui-Jun Yin, Da-Zhuo Shi, Ke-Ji Chen. Chinese herb and formulas for promoting blood circulation and removing blood stasis and antiplatelet therapies. Evidence-based complementary and alternative medicine : eCAM. 2012; 2012(?):184503. doi: 10.1155/2012/184503. [PMID: 22454656]
  • Sarah Jones, Richard J Evans, Martyn P Mahaut-Smith. Extracellular Ca(2+) modulates ADP-evoked aggregation through altered agonist degradation: implications for conditions used to study P2Y receptor activation. British journal of haematology. 2011 Apr; 153(1):83-91. doi: 10.1111/j.1365-2141.2010.08499.x. [PMID: 21332705]
  • David Iyú, Jackie R Glenn, Ann E White, Sue C Fox, Stan Heptinstall. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist. Arteriosclerosis, thrombosis, and vascular biology. 2011 Feb; 31(2):416-22. doi: 10.1161/atvbaha.110.219501. [PMID: 21106949]
  • Aurélie C Fabre, Camille Malaval, Abduelhakem Ben Addi, Céline Verdier, Véronique Pons, Nizar Serhan, Laeticia Lichtenstein, Guillaume Combes, Thierry Huby, François Briand, Xavier Collet, Niels Nijstad, Uwe J F Tietge, Bernard Robaye, Bertrand Perret, Jean-Marie Boeynaems, Laurent O Martinez. P2Y13 receptor is critical for reverse cholesterol transport. Hepatology (Baltimore, Md.). 2010 Oct; 52(4):1477-83. doi: 10.1002/hep.23897. [PMID: 20830789]
  • José A Barrabés, Javier Inserte, Maribel Mirabet, Adoración Quiroga, Victor Hernando, Jaume Figueras, David Garcia-Dorado. Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts. Thrombosis and haemostasis. 2010 Jul; 104(1):128-35. doi: 10.1160/th09-07-0440. [PMID: 20431845]
  • Shaker A Mousa, Walter P Jeske, Jawed Fareed. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2010 Apr; 16(2):170-6. doi: 10.1177/1076029609355589. [PMID: 20299391]
  • H J Bouman, J W van Werkum, G Rudez, F W G Leebeek, A Kruit, C M Hackeng, J M Ten Berg, M P M de Maat, H J T Ruven. The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor. Thrombosis and haemostasis. 2010 Feb; 103(2):379-86. doi: 10.1160/th09-06-0367. [PMID: 20126830]
  • Nadia M Bambace, Jamie E Levis, Chris E Holmes. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets. 2010; 21(2):85-93. doi: 10.3109/09537100903470298. [PMID: 20063989]
  • Shaker A Mousa, Walter P Jeske, Jawed Fareed. Prasugrel: a novel platelet ADP P2Y(12) receptor antagonist. Methods in molecular biology (Clifton, N.J.). 2010; 663(?):221-8. doi: 10.1007/978-1-60761-803-4_8. [PMID: 20617420]
  • Aino Lepäntalo, Kari S Virtanen, Julio C Reséndiz, Jussi Mikkelsson, Leena E Viiri, Pekka J Karhunen, Riitta Lassila. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor. Thrombosis research. 2009 Jun; 124(2):193-8. doi: 10.1016/j.thromres.2009.01.009. [PMID: 19232433]
  • H J Bouman, J W van Werkum, C M Hackeng, N Clappers, J M Ten Berg. Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation. 2009 May; 17(5):195-8. doi: 10.1007/bf03086246. [PMID: 19484155]
  • Andreas C Eriksson, Per A Whiss. Characterization of static adhesion of human platelets in plasma to protein surfaces in microplates. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2009 Apr; 20(3):197-206. doi: 10.1097/mbc.0b013e328327353d. [PMID: 19657317]
  • Kenneth A Jacobson, Andrei A Ivanov, Sonia de Castro, T Kendall Harden, Hyojin Ko. Development of selective agonists and antagonists of P2Y receptors. Purinergic signalling. 2009 Mar; 5(1):75-89. doi: 10.1007/s11302-008-9106-2. [PMID: 18600475]
  • Steen Husted, J J J van Giezen. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovascular therapeutics. 2009; 27(4):259-74. doi: 10.1111/j.1755-5922.2009.00096.x. [PMID: 19604248]
  • Stan Heptinstall, David Iyu Espinosa, Panagiotis Manolopoulos, Jackie R Glenn, Ann E White, Andrew Johnson, Natalia Dovlatova, Sue C Fox, Jane A May, David Hermann, Olafur Magnusson, Kari Stefansson, Dan Hartman, Mark Gurney. DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease. Platelets. 2008 Dec; 19(8):605-13. doi: 10.1080/09537100802351073. [PMID: 19012178]
  • Bernát János Béres, Emese Tóth-Zsámboki, Katarína Vargová, Adám László, Tamás Masszi, Gábor Kerecsen, István Préda, Róbert Gábor Kiss. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. Thrombosis and haemostasis. 2008 Nov; 100(5):829-38. doi: 10.1160/th08-03-0158. [PMID: 18989527]
  • Natalia Dovlatova, Yanushi D Wijeyeratne, Susan C Fox, Panagiotis Manolopoulos, Andrew J Johnson, Ann E White, M Liaque Latif, Vera Ralevic, Stanley Heptinstall. Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor. Thrombosis and haemostasis. 2008 Aug; 100(2):261-70. doi: 10.1160/th07-10-0601. [PMID: 18690346]
  • Heather M Judge, Robert J Buckland, Atsuhiro Sugidachi, Joseph A Jakubowski, Robert F Storey. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets. 2008 Mar; 19(2):125-33. doi: 10.1080/09537100701694144. [PMID: 18297550]
  • Lian Zhao, Leonie Gaudry, Scott Dunkley, Tim Brighton, Zhi Xin Guo, Zheng Liang Ye, Run Zhi Luo, Colin N Chesterman. Modulation of platelet and leucocyte function by a Chinese herbal formulation as compared with conventional antiplatelet agents. Platelets. 2008 Feb; 19(1):24-31. doi: 10.1080/09537100701286123. [PMID: 18231935]
  • Ruben G Xavier, Ann E White, Susan C Fox, Robert G Wilcox, Stan Heptinstall. Enhanced platelet aggregation and activation under conditions of hypothermia. Thrombosis and haemostasis. 2007 Dec; 98(6):1266-75. doi: 10.1160/th07-03-0189. [PMID: 18064324]
  • Nathaniel J Madsen, Chris E Holmes, Feliciano A Serrano, Burton E Sobel, David J Schneider. Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents. The American journal of cardiology. 2007 Aug; 100(4):722-7. doi: 10.1016/j.amjcard.2007.03.091. [PMID: 17697836]
  • Sandra M Penz, Armin J Reininger, Orsolya Toth, Hans Deckmyn, Richard Brandl, Wolfgang Siess. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. Thrombosis and haemostasis. 2007 Mar; 97(3):435-43. doi: . [PMID: 17334511]
  • H Shankar, A Garcia, J Prabhakar, S Kim, S P Kunapuli. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. Journal of thrombosis and haemostasis : JTH. 2006 Mar; 4(3):638-47. doi: 10.1111/j.1538-7836.2006.01789.x. [PMID: 16460446]
  • S Nylander, K Johansson, J J J Van Giezen, T L Lindahl. Evaluation of platelet function, a method comparison. Platelets. 2006 Feb; 17(1):49-55. doi: 10.1080/09537100500197448. [PMID: 16308187]
  • Miles W H Behan, Susan C Fox, Stan Heptinstall, Robert F Storey. Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. Platelets. 2005 Mar; 16(2):73-80. doi: 10.1080/09537100400005634. [PMID: 15823862]
  • Catherine Leon, Catherine Ravanat, Monique Freund, Jean-Pierre Cazenave, Christian Gachet. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arteriosclerosis, thrombosis, and vascular biology. 2003 Oct; 23(10):1941-7. doi: 10.1161/01.atv.0000092127.16125.e6. [PMID: 12933533]
  • Kenneth A Jacobson, Michael F Jarvis, Michael Williams. Purine and pyrimidine (P2) receptors as drug targets. Journal of medicinal chemistry. 2002 Sep; 45(19):4057-93. doi: 10.1021/jm020046y. [PMID: 12213051]
  • Filip Jacobsson, Eva Swahn, Lars Wallentin, Mikael Ellborg. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clinical therapeutics. 2002 May; 24(5):752-65. doi: 10.1016/s0149-2918(02)85149-9. [PMID: 12075943]
  • R F Storey, K G Oldroyd, R G Wilcox. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thrombosis and haemostasis. 2001 Mar; 85(3):401-7. doi: 10.1055/s-0037-1615596. [PMID: 11307804]
  • R F Storey, H M Sanderson, A E White, J A May, K E Cameron, S Heptinstall. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. British journal of haematology. 2000 Sep; 110(4):925-34. doi: 10.1046/j.1365-2141.2000.02208.x. [PMID: 11054084]